Recalibration of blood analytes over 25 years in the atherosclerosis risk in communities study: impact of recalibration on chronic kidney disease prevalence and incidence.
about
Change in novel filtration markers and risk of ESRD.Storage Time and Urine Biomarker Levels in the ASSESS-AKI StudyThe Association of Socioeconomic Status With Subclinical Myocardial Damage, Incident Cardiovascular Events, and Mortality in the ARIC Study.Relationship of the American Heart Association's Impact Goals (Life's Simple 7) With Risk of Chronic Kidney Disease: Results From the Atherosclerosis Risk in Communities (ARIC) Cohort StudyIterative Outlier Removal: A Method for Identifying Outliers in Laboratory Recalibration Studies.25-Hydroxyvitamin D Levels and Markers of Subclinical Myocardial Damage and Wall Stress: The Atherosclerosis Risk in Communities Study.Comparative prognostic performance of definitions of prediabetes: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study.Dietary Protein Sources and Risk for Incident Chronic Kidney Disease: Results From the Atherosclerosis Risk in Communities (ARIC) Study.DASH (Dietary Approaches to Stop Hypertension) Diet and Risk of Subsequent Kidney Disease.Six-Year Change in High-Sensitivity Cardiac Troponin T and Risk of Subsequent Coronary Heart Disease, Heart Failure, and Death.Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease.Thyroid function, reduced kidney function and incident chronic kidney disease in a community-based population: the Atherosclerosis Risk in Communities study.Race, APOL1 Risk, and eGFR Decline in the General Population.Association of a Biomarker of Glucose Peaks, 1,5-Anhydroglucitol, With Subclinical Cardiovascular DiseaseEpigenome-wide association studies identify DNA methylation associated with kidney function.Prediction of Type 2 Diabetes by Hemoglobin A1c in Two Community-Based Cohorts.Relation of Lifestyle Factors and Life's Simple 7 Score to Temporal Reduction in Troponin Levels Measured by a High-Sensitivity Assay (from the Atherosclerosis Risk in Communities Study).
P2860
Q35772896-5DF1933D-C881-422C-A2AB-D4BC10663440Q36176098-911373D0-6253-47E9-9AD6-C3CEB87277F9Q36634511-2B35D574-4E6D-40F4-9A09-0A22A470D0A8Q36877258-24513F74-02DD-475A-B355-E9D3C173FF3AQ37052909-86696544-24DB-4041-B0E4-FFFB0ED3CD1AQ37556051-5690E335-88C6-43E0-BBBA-7D404DCF1708Q38793504-C8628E7F-5CE9-428E-9595-AA26C496E2EAQ39033453-6ECED3F7-79CF-4495-B5A0-5083842E37B6Q39494977-D7A4C576-C91C-4597-87D4-E4D2B5C2C506Q39579918-E270653F-E445-400A-8E5C-36427B54A4C1Q40060474-CD439FC1-7C9F-49F5-9AA9-4E36C45FC238Q40615804-FA1894C4-135F-4DBC-B326-EB3A600CA877Q40860089-039B8D4C-DBD7-4596-9558-358D60C10025Q41640157-0A508ECC-2015-40B0-95C6-A40255939260Q47118222-91277C07-6B29-423B-A410-BE9449417FC6Q47709487-B7506EE5-68BD-44E7-9EAC-1A52334C9415Q51770699-F4993ADF-8547-490F-A426-731381D4C922
P2860
Recalibration of blood analytes over 25 years in the atherosclerosis risk in communities study: impact of recalibration on chronic kidney disease prevalence and incidence.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Recalibration of blood analyte ...... ease prevalence and incidence.
@ast
Recalibration of blood analyte ...... ease prevalence and incidence.
@en
type
label
Recalibration of blood analyte ...... ease prevalence and incidence.
@ast
Recalibration of blood analyte ...... ease prevalence and incidence.
@en
prefLabel
Recalibration of blood analyte ...... ease prevalence and incidence.
@ast
Recalibration of blood analyte ...... ease prevalence and incidence.
@en
P2093
P2860
P50
P1433
P1476
Recalibration of blood analyte ...... sease prevalence and incidence
@en
P2093
Christie M Ballantyne
Christina M Parrinello
Elizabeth Selvin
John H Eckfeldt
P2860
P304
P356
10.1373/CLINCHEM.2015.238873
P407
P577
2015-05-07T00:00:00Z